iral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment  Drug: remdesivir, standard of care  United States, Hong Kong,  600, all, 18 years and older  Treatment  Experimental: remdesivir, 5 days